Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Aaron T. Gerds, Jingbo Yu, Anne Shah, Ann Xi, Shambhavi Kumar, Robyn Scherber & Shreekant Parasuraman. (2023) Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs. Journal of Medical Economics 26:1, pages 843-849.
Read now
Read now
Lise Skovgaard Svingel, Sarah Friis Christensen, Anders Kjærsgaard, Anna Stenling, Björn Paulsson, Christen Lykkegaard Andersen, Christian Fynbo Christiansen, Jesper Stentoft, Jørn Starklint, Marianne Tang Severinsen, Mette Borg Clausen, Morten Hagemann Hilsøe, Hans Carl Hasselbalch, Henrik Frederiksen, Marie Bak & Ellen Margrethe Mikkelsen. (2023) Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study. Acta Oncologica 62:10, pages 1286-1294.
Read now
Read now
James T. England & Vikas Gupta. (2022) Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis. Expert Opinion on Pharmacotherapy 23:15, pages 1677-1686.
Read now
Read now
Articles from other publishers (6)
Aniket Bankar, Wing C. Chan, Ning Liu, Matthew Cheung, Shabbir Alibhai & Vikas Gupta. (2023) Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study. Blood Advances 7:17, pages 5014-5026.
Crossref
Crossref
Sarah Friis Christensen, Lise Skovgaard Svingel, Anders Kjærsgaard, Anna Stenling, Bianka Darvalics, Björn Paulsson, Christen Lykkegaard Andersen, Christian Fynbo Christiansen, Jesper Stentoft, Jørn Starklint, Marianne Tang Severinsen, Mette Borg Clausen, Morten Hagemann Hilsøe, Hans Carl Hasselbalch, Henrik Frederiksen, Ellen Margrethe Mikkelsen & Marie Bak. (2022) Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study. European Journal of Haematology 109:5, pages 526-541.
Crossref
Crossref
Jill Brennan-Cook & Allen Cadavero. (2022) Professional Case Management in Outpatient Settings for Patients With Myeloproliferative Neoplasms. Professional Case Management 27:6, pages 271-276.
Crossref
Crossref
Monia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, Claire Harrison, Steffen Koschmieder, Heinz Gisslinger, Alberto Álvarez-Larrán, Valerio De Stefano, Paola Guglielmelli, Francesca Palandri, Francesco Passamonti, Giovanni Barosi, Richard T Silver, Rüdiger Hehlmann, Jean-Jacques Kiladjian & Tiziano Barbui. (2022) Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. The Lancet Haematology 9:4, pages e301-e311.
Crossref
Crossref
Aniket Bankar, Shabbir Alibhai, Elliot Smith, Dongyang Yang, Sarah Malik, Verna Cheung, Nancy Siddiq, Jaime Claudio, Andrea Arruda, Hubert Tsui, Jose‐Mario Capo‐Chichi, James A. Kennedy, Caroline McNamara, Hassan Sibai, Dawn Maze, Wei Xu & Vikas Gupta. (2021) Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study. British Journal of Haematology 194:3, pages 557-567.
Crossref
Crossref
Vikas GuptaSoyoung Kim, Zhen-Huan Hu, Ying LiuMahmoud AljurfUlrike Bacher, Amer BeitinjanehJean-Yves CahnJan CernyEdward CopelanShahinaz M. Gadalla, Robert Peter Gale, Siddhartha GangulyBiju George, Aaron T. Gerds, Usama GergisBetty K. HamiltonShahrukh Hashmi, Gerhard C. Hildebrandt, Rammurti T. KambleTamila Kindwall-KellerHillard M. Lazarus, Jane L. LiesveldMark Litzow, Richard T. MaziarzTaiga Nishihori, Richard F. Olsson, David Rizzieri, Bipin N. SavaniSachiko Seo, Melhem SolhJeff Szer, Leo F. VerdonckBaldeep WirkAnn Woolfrey, Jean A. Yared, Edwin P. AlyeaUday R. Popat, Ronald M. Sobecks, Bart L. Scott, Ryotaro Nakamura & Wael Saber. (2020)
Comparison of outcomes of HCT in blast phase of
BCR-ABL1
− MPN with de novo AML and with AML following MDS
. Blood Advances 4:19, pages 4748-4757.
Crossref
Crossref